Question

A 72-year-old woman with heart failure with reduced ejection fraction (LVEF 30%) is stable on Ramipril and Furosemide. According to NICE heart failure guidance, which additional disease-modifying drug class should be routinely considered alongside an evidence-based beta-blocker?

Accepted Answer

Mineralocorticoid receptor antagonist (e.g. Spironolactone)

Answer

Calcium-channel blocker (Amlodipine)

Answer

Ivabradine

Answer

Loop diuretic up-titration

Answer

Thiazide diuretic

Practice question

A 72-year-old woman with heart failure with reduced ejection fraction (LVEF 30%) is stable on Ramipril and Furosemide. According to NICE heart failure guidance, which additional disease-modifying drug class should be routinely considered alongside an evidence-based beta-blocker?